ArticleHuman vaccines & immunotherapeutics2025
A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlocking the value of RSV vaccination in Japan: a return on investment analysis using an integrated actuarial-macroeconomic model.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally aging demographics necessitate proactive public health interventions like adult immunization programs, but comprehensive estimates of their socioeconomic value are lacking or narrow in perspective, risking suboptimal decision-making. To estimate the socioeconomic value of adult immunization programs for influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus across ten countries. Benefit-cost analysis using static disease models and a reference case framework to quantify net monetary benefits of immunization programs using different monetization approaches for non-monetary benefits. Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, US. Based on the lowest and highest valuations of non-monetary benefits, across all immunization programs, the mean benefit-cost ratios (BCRs) ranged from 5 to 19, suggesting substantial positive returns. Mortality-focused disease programs like influenza (BCRs 6-22) and pneumococcal disease (BCRs 15-33) showed the highest returns. The emerging respiratory syncytial virus program also demonstrated high potential positive returns (BCRs 6-16). Herpes zoster programs which primarily affect quality of life also yielded positive returns with BCRs of 2-4. Across all data points, 95% of estimated BCRs exceeded the cost-neutral 1.0 threshold. Adult immunization programs for influenza, pneumococcal disease, respiratory syncytial virus and herpes zoster consistently show positive returns on investment across a diversity of countries. Funding these programs provides long-term benefits and may help to mitigate upcoming global demographic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.